Lorus Therapeutics has filed an investigational new drug (IND) application with the US Food and Drug Administration for LOR-253, an anti-cancer drug candidate.

The application is for a first-in-human phase I dose escalation trial in advanced or metastatic solid tumours to assess antitumour activity, safety and tolerability in cancer patients.

The trial will be conducted at Memorial Sloan-Kettering Cancer Center in New York, US.

Preclinical studies have demonstrated that the compound has selective and antitumour activity against colon and non-small cell lung cancer, and is less toxic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData